Gary F. Baxter

Citeras av

	Alla	Sedan 2020
Citat	15037	1954
h-index	64	24
i10-index	113	49

900

450

225

675

19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202585 100 197 274 336 405 410 518 561 549 547 633 604 650 689 898 846 808 727 759 672 614 518 515 423 434 422 329 305 41

Offentlig åtkomst

Visa alla

16 artiklar

6 artiklar

tillgänglig

inte tillgänglig

Enligt krav från finansiärer

Medförfattare

Derek YellonProfessor of Molecular & Cellular CardiologyVerifierad e-postadress på ucl.ac.uk
Péter FerdinandySemmelweis University, Budapest; Pharmahungary Group, Szeged, HungaryVerifierad e-postadress på pharmahungary.com
Gerd HeuschProfessor, Universität Duisburg-EssenVerifierad e-postadress på uk-essen.de
Helen MaddockDirector of the Biomolecular Sciences ARG, Coventry UniversityVerifierad e-postadress på coventry.ac.uk
Zoltan Giriczsenior research associate, Semmelweis UniversityVerifierad e-postadress på net.sote.hu
Görbe AnikóSemmelweis University, University of SzegedVerifierad e-postadress på med.u-szeged.hu
M WhitemanVerifierad e-postadress på exeter.ac.uk
JUAN-CARLOS KaskiProfessor of Cardiovascular ScienceVerifierad e-postadress på sgul.ac.uk
Tamás CsontUniversity of SzegedVerifierad e-postadress på med.u-szeged.hu
Sandrine LecourProfessor, University of Cape TownVerifierad e-postadress på uct.ac.za
Jakob Vinten-JohansenProfessor Emeritus, Emory UniversityVerifierad e-postadress på emory.edu
Marko KeracAssociate Professor, Global Child Health & Nutrition, LSHTMVerifierad e-postadress på lshtm.ac.uk
Matt WrightSenior Lecturer, King's College LondonVerifierad e-postadress på kcl.ac.uk
Zoltán SzilvássyUniversity of DebrecenVerifierad e-postadress på unideb.hu
Matthias TotzeckUniv.-Prof., University Duisburg-Essen, University Hospital Essen, Medical FacultyVerifierad e-postadress på uk-essen.de
Richard SchulzProfessor, Departments of Pediatrics & Pharmacology, University of Alberta, Edmonton CanadaVerifierad e-postadress på ualberta.ca
David P JenkinsRoyal Papworth hospital, Cambridge, UKVerifierad e-postadress på doctors.org.uk
Charles D CoxGroup Leader, Victor Chang Cardiac Research InstituteVerifierad e-postadress på victorchang.edu.au
Johannes-Peter StaschProfessor für Arzneimittelforschung; Chief Scientist Bayer AGVerifierad e-postadress på bayer.com
Vicky LipscombProfessor of Small Animal Surgery, Royal Veterinary CollegeVerifierad e-postadress på rvc.ac.uk

Följ

Gary F. Baxter

Professor of Pharmacology, School of Pharmacy & Pharmaceutical Sciences, Cardiff university, UK

Verifierad e-postadress på cardiff.ac.uk

Cardiovascular Pharmacology


Titel Sortera efter citat Sortera efter år Sortera efter titel	Citeras av Citeras av	År
Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning P Ferdinandy, R Schulz, GF Baxter Pharmacological reviews 59 (4), 418-458, 2007	1030	2007
Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? DJ Hausenloy, HL Maddock, GF Baxter, DM Yellon Cardiovascular research 55 (3), 534-543, 2002	802	2002
Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning P Ferdinandy, DJ Hausenloy, G Heusch, GF Baxter, R Schulz, FO Levy Pharmacological reviews 66 (4), 1142-1174, 2014	693	2014
Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of … M Ovize, GF Baxter, F Di Lisa, P Ferdinandy, D Garcia-Dorado, ... Cardiovascular research 87 (3), 406-423, 2010	648	2010
Exogenous hydrogen sulfide (H₂S) protects against regional myocardial ischemia–reperfusion injury: Evidence for a role of K_ATP channels D Johansen, K Ytrehus, GF Baxter Basic research in cardiology 101, 53-60, 2006	451	2006
Ischaemic preconditioning: present position and future directions DM Yellon, GF Baxter, D Garcia-Dorado, G Heusch, MS Sumeray Cardiovascular research 37 (1), 21-33, 1998	445	1998
A “second window of protection” or delayed preconditioning phenomenon: future horizons for myocardial protection? DM Yellon, GF Baxter Journal of molecular and cellular cardiology 27 (4), 1023-1034, 1995	390	1995
Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin D Roy, J Quiles, DC Gaze, P Collinson, JC Kaski, GF Baxter Heart 92 (1), 113-114, 2006	389	2006
Renal ischemia preconditions myocardium: role of adenosine receptors and ATP-sensitive potassium channels TJ Pell, GF Baxter, DM Yellon, GM Drew American Journal of Physiology-Heart and Circulatory Physiology 275 (5 …, 1998	384	1998
Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. GF Baxter, MS Marber, VC Patel, DM Yellon Circulation 90 (6), 2993-3000, 1994	369	1994
Characterisation of the infarct-limiting effect of delayed preconditioning: timecourse and dose-dependency studies in rabbit myocardium GF Baxter, FM Goma, DM Yellon Basic research in cardiology 92, 159-167, 1997	326	1997
B-type natriuretic peptide limits infarct size in rat isolated hearts via K_ATP channel opening SP D'souza, DM Yellon, C Martin, R Schulz, G Heusch, A Onody, ... American Journal of Physiology-Heart and Circulatory Physiology 284 (5 …, 2003	320	2003
Autocrine and paracrine actions of natriuretic peptides in the heart SP D'Souza, M Davis, GF Baxter Pharmacology & therapeutics 101 (2), 113-129, 2004	300	2004
Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury MM Mocanu, GF Baxter, DM Yellon British journal of pharmacology 130 (2), 197-200, 2000	293	2000
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations DJ Hausenloy, G Baxter, R Bell, HE Bøtker, SM Davidson, J Downey, ... Basic research in cardiology 105, 677-686, 2010	286	2010
Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality? DM Yellon, GF Baxter Heart 83 (4), 381-387, 2000	245	2000
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide MM Mocanu, HL Maddock, GF Baxter, CL Lawrence, NB Standen, ... Circulation 103 (25), 3111-3116, 2001	226	2001
Cyclic GMP and protein kinase‐G in myocardial ischaemia‐reperfusion: opportunities and obstacles for survival signaling DS Burley, P Ferdinandy, GF Baxter British journal of pharmacology 152 (6), 855-869, 2007	223	2007
Involvement of protein kinase C in the delayed cytoprotection following sublethal ischaemia in rabbit myocardium GF Baxter, FM Goma, DM Yellon British journal of pharmacology 115 (2), 222-224, 1995	222	1995
Regulation of cardiovascular cell function by hydrogen sulfide (H₂S) DJ Elsey, RC Fowkes, GF Baxter Cell Biochemistry and Function: Cellular biochemistry and its modulation by …, 2010	212	2010

Systemet kan inte utföra åtgärden just nu. Försök igen senare.

Artiklar 1–20

Citat per år

Dubblettcitat

Sammanfogade citat

Lägg till medförfattareMedförfattare

Följ

Citeras av

Medförfattare